Pharmacological basis and clinical evidence of dabigatran therapy

被引:17
作者
Redondo, Santiago [1 ]
Martinez, Maria-Paz [1 ]
Ramajo, Marta [2 ]
Navarro-Dorado, Jorge [2 ]
Barez, Abelardo [1 ]
Tejerina, Teresa [2 ]
机构
[1] Hosp Nuestra Senora Sonsoles, Serv Hematol, Avila, Spain
[2] Univ Complutense Madrid, Sch Med, Dept Pharmacol, E-28040 Madrid, Spain
关键词
dabigatran; thrombosis; surgery; atrial fibrillation; DIRECT THROMBIN INHIBITOR; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; ANTICOAGULANT ACTIVITY; RANDOMIZED-TRIAL; KNEE REPLACEMENT; ETEXILATE; PREVENTION; ENOXAPARIN;
D O I
10.1186/1756-8722-4-53
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administration and the European Medicines Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.
引用
收藏
页数:7
相关论文
共 21 条
[1]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[2]   Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].
Eerenberg, Elise S. ;
Kamphuisen, Pieter W. ;
Sijpkens, Meertien K. ;
Meijers, Joost C. ;
Buller, Harry R. ;
Levi, Marcel .
CIRCULATION, 2011, 124 (14) :1573-1579
[3]   Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].
Eriksson, B. I. ;
Dahl, O. E. ;
Rosencher, N. ;
Kurth, A. A. ;
Van Dijk, N. ;
Frostick, S. P. ;
Kalebo, P. ;
Christiansen, A. V. ;
Hantel, S. ;
Hettiarachchi, R. ;
Schnee, J. ;
Buller, H. R. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185
[4]   Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].
Eriksson, Bengt I. ;
Dahl, Ola E. ;
Rosencher, Nadia ;
Kurth, Andreas A. ;
van Dijk, C. Niek ;
Frostick, Simon P. ;
Prins, Martin H. ;
Hettiarachchi, Rohan ;
Hantel, Stefan ;
Schnee, Janet ;
Bueller, Harry R. .
LANCET, 2007, 370 (9591) :949-956
[5]   A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].
Eriksson, BI ;
Dahl, OE ;
Büller, HR ;
Hettiarachchi, R ;
Rosencher, N ;
Bravo, ML ;
Ahnfelt, L ;
Piovella, F ;
Stangier, J ;
Kälebo, P ;
Reilly, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111
[6]   Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement:: BISTRO I [J].
Eriksson, BI ;
Dahl, OE ;
Ahnfelt, L ;
Kälebo, P ;
Stangier, J ;
Nehmiz, G ;
Hermansson, K ;
Kohlbrenner, V .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (09) :1573-1580
[7]  
European Medicines Agency, DAB LAB
[8]   Dabigatran with or without concomitant Aspirin compared with Warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study) [J].
Ezekowitz, Michael D. ;
Reilly, Paul A. ;
Nehmiz, Gerhard ;
Simmers, Timothy A. ;
Nagarakanti, Rangadham ;
Parcham-Azad, Kambiz ;
Pedersen, K. Erik ;
Lionetti, Dominick A. ;
Stangier, Joachim ;
Wallentin, Lars .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (09) :1419-1426
[9]  
Food and Drug Administration, DAB LAB
[10]   Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials [J].
Friedman, R. J. ;
Dahl, O. E. ;
Rosencher, N. ;
Caprini, J. A. ;
Kurth, A. A. ;
Francis, C. W. ;
Clemens, A. ;
Hantel, S. ;
Schnee, J. M. ;
Eriksson, B. I. .
THROMBOSIS RESEARCH, 2010, 126 (03) :175-182